Immediate eradication of Helicobacter pylori in patients with previously documented peptic ulcer disease: Clinical and economic effects

American Journal of Gastroenterology

Volumn 92, Issue 11, 1997, Pages 2017-2024

  Fendrick, A Mark ^a   McCort, Jane T ^b   Chernew, Michael E ^b   Hirth, Richard A ^b   Patel, Chirag ^b   Bloom, Bernard S ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR; STOMACH SECRETION INHIBITOR;

ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GASTRITIS; GASTROINTESTINAL ENDOSCOPY; HEALTH CARE COST; HELICOBACTER PYLORI; HUMAN; MEDICAL DECISION MAKING; MODEL; PEPTIC ULCER; PRIORITY JOURNAL; TREATMENT OUTCOME; ULCER HEALING;

ANTI-ULCER AGENTS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MARKOV CHAINS; PEPTIC ULCER; RECURRENCE; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 0030725512     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (91)

1. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. Helicobacter pylori in peptic ulcer disease. JAMA 1994;272:65-9.
2. Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988;2:1437-42.
3. Hentschel E, Brandstatter G, Dragosics B, et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993;328: 308-12.
4. Hosking SW, Ling TKW, Chung SCS, et al. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: Randomized controlled trial. Lancet 1994;343:508-10.
5. Labenz J, Borsch G. Highly significant change of the clinical course of relapsing and complicated peptic ulcer disease after cure of Helicobacter pylori infection. Am J Gastroenterol 1994;89:1785-8.
6. Graham DY, Lew GM, Evans DG, et al. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing: A randomized controlled trial. Ann Intern Med 1991;115:266-9.
7. Marshall BJ. Helicobacter pylori: The etiological agent for peptic ulcer. JAMA 1995;274:1064-6.
8. Blaser MJ. Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastroenterology 1992;102:720-7.
9. Fendrick AM, Hirth RA, Chernew ME. Differences between generalist and specialist physicians regarding Helicobacter pylori and peptic ulcer disease. Am J Gastroenterol 1996;91:1544-8.
10. Sonnenberg A, Townsend WF. Costs of duodenal ulcer therapy with antibiotics. Arch Intern Med 1995;155:922-8.
11. Imperiale T, Speroff T, Cebul RD, et al. A cost analysis of alternative treatments for duodenal ulcer. Ann Intern Med 1995;123:665-72.
12. O'Brien B, Goeree R, Mohamed H, et al. Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcer in Canada. Arch Intern Med 1995;155:1958-64.
13. Unge P, Jonsson B, Stalhammar N-O. The cost-effectiveness of Helicobacter pylori eradication versus maintenance and episodic treatment in duodenal ulcer patients in Sweden. PharmacoEconomics 1995;8: 410-27.
14. Kurata JH. Ulcer epidemiology: An overview and proposed research framework. Gastroenterology 1989;96:569-76.
15. McDonnell WM, Flanagan PS, Fendrick AM. Chronic H2 antagonist use at a veterans affairs medical center. Am J Gastroenterol 1996;91: 1920A.
16. Taylor JL, Zagari M, Murphy K, et al. Pharmacoeconomic comparison of treatments for the eradication of Helicobacler pylori. Arch Intern Med 1997;157:87-97.
17. Elashoff JD. Evaluating a Markov chain analysis. Gastroenterology 1984;87:725-8.
18. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983;3:419-58.
19. Feldman M. The acid test. Making clinical sense of the Consensus Conference on Helicobacter pylori. JAMA 1994;272:70-1.
20. Evans DJ, Evans DG, Graham DY, et al. A sensitive and specific serologic test for detection of Campylobacter pylori infection. Gastroenterology 1989;96:1004-8.
21. Talley NJ, Kost L, Haddad A, et al. Comparison of commercial serological tests for detection of Helicobacter pylori antibodies. J Clin Microbiol 1992;30:3146-50.
22. Rauws EAJ, Tytgat GNJ. Care of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 1990;335:1233-5.
23. Cutler AF, Schubert TT. Long-term Helicobacter pylori recurrence after successful eradication with triple therapy. Am J Gastroenterol 1993;88:1359-61.
24. Borody T, Andrews P, Mancuso N, et al. Helicobacter pylori reinfection 4 years post-eradication. Lancet 1992;339:1295.
25. Borody TJ, Andrews P, Mancuso N, et al. Helicobacter pylori reinfection rate in patients with cured duodenal ulcer. Am J Gastroenterol 1994;89:529-32.
26. Nichols L, Sughayer M, DeGirolami PC. Evaluation of diagnostic methods for Helicobacter pylori gastritis. Am J Clin Pathol 1991;95: 769-73.
27. Brown KE, Peura DA. Diagnosis of Helicobacter pylori infection. Gastroenterol Clinic North Am 1993;22:105-15.
28. Marshall BJ, Warren JR, Fraucis GJ, et al. Rapid urease test in the management of Campylobacter pylori-associated gastritis. Am J Gastroenterol 1987;82:200-4.
29. 14C-urea breath analysis: A non-invasive test for Campylobacter pylori in the stomach. Lancet 1987;1:1367-8.
30. Marshall BJ, Surveyor I. Carbon-14 urea breath test for the diagnosis of associated gastritis. J Nucl Med 1988;29:11-6.
31. Rudensky B, Braverman DZ, Dollberg L, et al. Comparison of different tests for Helicobacter pylori. Am J Gastroenterol 1990;85:325-6.
32. Walsh JH, Peterson WL. Drug therapy: The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995;33:984-91.
33. Soll AH. Medical treatment of peptic ulcer disease: Practice guidelines. JAMA 1996;275:622-9.
34. Bell GD, Powell KU, Burridge SM, et al. Helicobacter pylori eradication: Efficacy and side effect profile of a combination of omeprazole, amoxicillin and metronidazole compared with four alternative regimens. Q J Med 1993;86:743-50.
35. Borody TJ, Brandi S, Andrews P, et al. Use of high efficacy lower dose triple therapy to reduce side effects of eradicating Helicobacter pylori. Am J Gastroenterol 1994;89:33-8.
36. Cutler AF, Schubert TT. Patient factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroenterol 1993;88:505-9.
37. Gough KR, et al. Ranitidine and cimetidine in prevention of duodenal ulcer relapse: A double-blind, randomized, multicentre, comparative trial. Lancet 1984;2:659-62.
38. Elashoff JD, Van Deventer G, Ready TJ, et al. Long-term follow-up of duodenal ulcer patients. J Clin Gastroenterol 1983;5:509-15.
39. Lin JT, Wang JT, Wu MS, et al. Prospective, randomized study of H2-blocker and triple therapy for duodenal ulcer treatment and the eradication of Helicobacter pylori. J Fomos Med Assoc 1994;93:368-73.
40. Bodemar G, Walan A. Two year follow-up after one year's treatment with cimetidine or placebo. Lancet 1980;1:38-9.
41. Bolin TD, Billington BP, Davis AE. Comparison of ranitidine and cimetidine as maintenance therapy in the prevention of duodenal ulcer recurrence. Aust N Z J Med 1983;13:440.
42. Hui WH, Lam SK, et al. Maintenance therapy for duodenal ulcer: A randomized controlled comparison of seven forms of treatment. Am J Med 1992;92:265-74.
43. Van Deventer GM, Elashoff JD, Reedy TJ, et al. A randomized study of maintenance therapy with ranitidine to prevent the recurrence of duodenal ulcer. N Engl J Med 1989;320:1113-9.
44. Mantzaris GJ, Hatzis A, Tamvakologos G, et al. Prospective, randomized investigator-blind trials of Helicobacter pylori infection treatment in patients with refractory duodenal ulcers: Healing and long-term relapse rates. Dig Dis Sci 1993;38:1132-6.
45. Burland WL, Hawkins BW, Beresford J. Cimetidine treatment for the prevention of recurrence of duodenal ulcer: An international collaborative study. Postgrad Med J 1980;56:173-6.
46. Gray GR, Smith IS, Mackenzie I, et al. Long term cimetidine in the management of severe duodenal ulcer dyspepsia. Gastroenterology 1978;74:397-401.
47. McIntosh, et al. Patterns of dyspepsia during the course of duodenal ulcer. J Clin Gastroenterol 1991;13:506-13.
48. Peto R, Pike C, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: No. 2. Analysis and samples. Br J Cancer 1977;35:1-39.
49. Flind AC, Beresford J. Controlled trial of cimetidine for symptomatic treatment of duodenal ulcers. Br Med J (Clin Res Ed) 1983;286: 1284-5.
50. Boyd EJS, Wilson JA, Wormsley KG. The fate of asymptomatic recurrences of duodenal ulcer. Scand J Gastroenterol 1984;19:808-12.
51. Paoluzi P, Ricotta G, Ripoli F, et al. Incompletely and completely healed duodenal ulcers' outcome in maintenance treatment: A double blind controlled study. Gut 1985;26:1080-5.
52. Susi D, Neri M, Ballone E, et al. Five-year maintenance treatment with ranitidine: Effects on the natural history of duodenal ulcer disease. Am J Gastroenterol 1994;89:26-32.
53. Rune SJ, Greibe J, Mollmon KM, et al. Recurrence of duodenal ulcer pain after treatment with cimetidine for four and eight weeks. Gut 1980;21:151-3.
54. Archambult AP, Pare P, Bailey RJ, et al. Omeprazole (20 mg daily) versus cimetidine (1200 mg daily) in duodenal ulcer healing and pain relief. Gastroenterology 1988;94:1130-4.
55. McLean AJ, Harrison PM, Byne AJ, et al. Relapse rates are more important than healing rates in determining the long-term outcome of duodenal ulcer therapy. Gastroenterology 1985;89:480-2.
56. Ho J, Lui I, Hui WM, et al. A study on the correlation of duodenal ulcer healing with Campylobacter-like organisms. J Gastroenterol Hepatol 1986;1:69-74.
57. Forbes GM, Glaser ME, Cullen DJE, et al. Duodenal ulcer treated with Helicobacter pylori eradication: Seven-year follow-up. Lancet 1994; 343:258-60.
58. Ippoliti A, Elashoff J, Cooney C, et al. Duodenal ulcer relapse after cimetidine withdrawal. Gastroenterology 1978;74:1047 (abstract).
59. Ippoliti A, Elashoff J, Valenzuela J, et al. Recurrent ulcer after successful treatment with cimetidine or antacid. Gastroenterology 1983; 85:875-80.
60. Bianchi Porro G, Petrillo M. The natural history of duodenal ulcer disease: The influence of H2-antagonist treatment. Scand J Gastroenterol 1986;21(suppl 121):46-52.
61. Freston JW. H2-receptor antagonists and duodenal ulcer recurrence: Analysis of efficacy and commentary on safety costs and patient selection. Am J Gastroenterol 1987;82:1242-9.
62. Robinson M. Review of peptic ulcer maintenance trials. Am J Med 1984;77(suppl 5B):23-9.
63. Holtmann G, Armstrong D. Does long-term maintenance therapy with ranitidine affect the natural course of duodenal ulcer disease? Eur J Gastroenterol Hepatol 1993;7:259-65.
64. Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer: A randomized, controlled study. Ann Intern Med 1992;116:705-8.
65. Tytgat GNJ, Noach L, Rauws EAJ. Helicobacter pylori. Scand J Gastroenterol 1991;26(suppl 187):1-8.
66. Korman MG, Hetzel DJ, Hansky J, et al. Relapse rate of duodenal ulcer after cessation of long-term cimetidine treatment: A double-blind controlled study. Dig Dis Sci 1980;25:88-91.
67. Alstead EM, Ryan FP, Holdsworth CD, et al. Ranitidine in the prevention of gastric and duodenal ulcer relapse. Gut 1983;24:418-20.
68. Anglo-Irish Long Term Cimetidine Study Group. Prophylaxis against duodenal (DU) and gastric ulcer (GU) recurrence using maintenance treatment (MT) with cimetidine (C) 4-year results. Gastroenterology 1985;88:1307 (abstract).
69. Boyd EJS, Wilson JA, Wormsley KG. The natural history of asymptomatic duodenal ulcer recurrences. Hepatogastroenterology 1984;31: 103 (abstract).
70. Guslandi M, Bierti L, Ballarin E, et al. Silent ulcer recurrences during maintenance treatment with H2-blockers. Gastroenterology 1983;84: 1178 (abstract).
71. Jorde R, Burhol PG. Asymptomatic peptic ulcer disease. Scand J Gastroenterol 1987;22:129-34.
72. Bardhan KD, Saul DM, Edwards JL, et al. Double-blind comparison of cimetidine and placebo in the maintenance of healing of chronic duodenal ulceration. Gut 1979;20:158-62.
73. Sonnenberg A. Comparison of different strategies for treatment of duodenal ulcer. Br Med J 1985;290:1185-7.
74. Penston JG. The effect of maintenance treatment with ranitidine on the complications of duodenal ulcer disease. Scand J Gastroenterol 1990; 25(suppl 177):52-6.
75. Schiller LR, Fordtran JS. Ulcer complications during short-term therapy of duodenal ulcer with active agents and placebo. Gastroenterology 1986;90:478-481.
76. Hillman AL, Eisenberg JM, Pauly MV, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med 1991;324:1362-5.
77. Graham DY. Helicobacter pylori: Its epidemiology and its role in duodenal ulcer disease. J Gastroenterol Hepatol 1991;6:105-13.
78. Blaser MJ, Perez-Perez GI, et al. Association of infection due to Helicobacter pylori with specific upper gastrointestinal pathology. Rev Infect Dis 1991;13(suppl 8):S704-8.
79. Borody TJ, George LL, Brandi S, et al. Helicobacter pylori-negative duodenal ulcer. Am J Gastroenterol 1991;86:1154-7.
80. Cheng EH, Bermanski P, Silversmith M, et al. Prevalence of Campylobacler pylori in esophagitis, gastritis, duodenal disease. Arch Intern Med 1989;149:1373-5.
81. Chiba N, Rao BV, Rademaker JW, et al. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 1992;87:1716-27.
82. Axon ATR. Campylobacter pylori therapy review. Scand J Gastroenterol 1989;24(suppl 160):35-8.
83. Bayerdorffer E, Miehlke S, et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 1995;108:1412-7.
84. Scheurer U, Witzel L, Halter F, et al. Gastric and duodenal ulcer healing under placebo treatment. Gastroenterology 1977;72:838-41.
85. Valenzuela JE, Berlin RG, Snape WJ, et al. U. S. experience with omeprazole in duodenal ulcer: Multicenter double-blind comparative study with ranitidine. Dig Dis Sci 1991;36:761-8.
86. Adarnek RJ, et al. Medium-term results of oral and intravenous omeprazole/amoxicillin Helicobacter pylori eradication therapy. Am J Gastroenterol 1994;89:39-42.
87. Lee FI, Colin-Jones DG, Golding PL, et al. Double-blind comparative study of omeprazole and ranitidine in patients with duodenal gastric ulcer: A multicentre trial. Gut 1990;31:653-6.
88. Dobrilla G, Barbara L, Bianchi Porro G, et al. Placebo controlled studies with ranitidine in duodenal ulcer. Scand J Gastroenterol 1981(suppl 69):101-7.
89. Bardhan KD, Bianchi Porro G, Bose K, et al. A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers. J Clin Gastroenterol 1986;8:408-13.
90. Simon B, Cremer M, Dammann HG, et al. 300 mg nizatidine at night versus 300 mg ranitidine at night in patients with duodenal ulcer: A multicentre trial in Europe. Scand J Gastroenterol 1987;22(suppl 134): 21-8.
91. Lauritsen K, Rune S, Bytzer P, et al. Effect of omeprazole and cimetidine on duodenal ulcer: A double-blind comparative trial. N Engl J Med 1985;312:958-61.